Core Viewpoint - The company has existing flu medication products and is developing new antiviral treatments, indicating a strong position in the respiratory infection market [2]. Product Overview - The company currently markets a mature flu medication, Compound Acetaminophen and Amantadine Capsules [2]. - An antiviral tablet is expected to receive approval for market launch in 2025, aimed at treating upper respiratory infections and influenza [2]. Research and Development - The company is conducting research on "Rui Xiang Su" for its effects on viral pneumonia in mouse models, showing safety and efficacy [2]. - A patent has been obtained for the application of "Rui Xiang Su" in the preparation of drugs for treating viral pneumonia [2]. - The company is the sole producer and seller of "Rui Xiang Su" capsules in China [2].
西点药业：公司是国内独家生产销售瑞香素胶囊的生产企业